New Breakthrough Drug, Dostarlimab Emerges for Cancer Treatment 

Onyebuchi Ezigbo in Abuja

The world is on the verge of attaining a massive breakthrough in the development of drug for the treatment of the dreaded cancer disease.
Dostarlimab drug approved by the United States Food and Drug Regulatory Authority is a monoclonal antibody used as an anti-cancer medication for the treatment of cancer. The drug regulatory authority also approved the trial test conducted in Dostarlimab on at least 300 patients with various cancer diseases.
Although the confirmation of the efficacy of the drug was still at its preliminary states, scientists said such a success rate had never been recorded in the history of cancer treatment

Doctors and medical experts in the United States said when administered to patients during drug trials, the cancer disease vanished completely.
A report on the medical breakthrough stated that the development for cancer treatment has left doctors stunned. In the drug trial exercise conducted in the United States, 18 patients with rectal cancer were administered with Dostarlimab.

According to the report, doctors said it was like a miracle when they achieved a 100 per cent success rate as the cancer vanished completely all the 18 patients.
It said each of the patients’ tumor disappeared entirely within the six months of treatment after post trial test.

The United States, dostarlimab was indicated for the treatment of adults with mismatch repair deficient (dMMR) recurrent or advanced endometrial cancer, as determined by an FDA-approved test, that has progressed on or following prior treatment with a platinum-containing regimen. Platinum-based agents such as cisplatin, carboplatin and oxaliplatin were mainstays of treatment when it comes to cancer chemotherapy treatment.   It is also indicated for the treatment of solid tumors.

In the European Union, dostarlimab is indicated as monotherapy for the treatment of adults with mismatch repair deficient (dMMR)/microsatellite instability-high (MSI H) recurrent or advanced endometrial cancer (EC) that has progressed on or following prior treatment with a platinum-containing regimen.

In August 2021, the US Food and Drug Administration (FDA) granted accelerated approval to dostarlimab for adults with mismatch repair deficient (dMMR) recurrent or advanced solid tumors, as determined by an FDA-approved test, that have progressed on or following prior treatment and who have no satisfactory alternative treatment options.